Transgenic and Targeting Shared Resource

转基因和靶向共享资源 项目摘要/摘要 转基因和靶向共享资源是CASE综合体的重要资产 癌症中心(Case CCC)成员的研究，由科学项目参与的广度和 反映在使用这一SR的大量调查人员身上。仅去年一年，就有45名调查人员，其中40% 是Case CCC成员，占总使用量的39%，而该中心7个项目中有5个使用了 高级转基因SR制造转基因、嵌合、基因敲除和敲入小鼠，并在 胚胎移植、冷冻保存、复活、体外受精和手术。成功的核心是 研究人员使用新的小鼠遗传模型是这个设施在咨询、教育和培训方面所发挥的作用， 以及服务后的支持。转基因SR的具体目标是： 1.为CASE CCC成员提供咨询、教育和培训。转基因技术的负责人 SR咨询癌症中心成员和他们的研究人员，以确保他们最好地利用 技术来满足他们的实验目标。CRISPR/CAS9技术的快速发展使得 咨询尤为重要。 2.为CASE CCC成员提供新的小鼠遗传模型。转基因SR产生了基因 以及时和具有成本效益的方式提供各种不同的小鼠。 3.通过直接互动和通过财富为CASE CCC成员提供后续支持 设施网站上提供的信息。 在最后的评价中，转基因SR被评为杰出的优点。在本供资周期(2012年-- 2016)，转基因SR为133名注册用户提供服务，其中41名(31%)是Case CCC 成员，代表中心7个项目中的5个。 利用CRISPR/Cas9对转基因SR进行基因打靶取得了很大的成功。自2014年以来，SR已经 使用这种方法成功地在小鼠身上完成了30多个新的基因靶向突变，绝大多数 它们都是致病的错义突变。转基因SR是转基因技术的先锋 应用CRISPR/CAS9技术的核心。在上一个资助期，转基因SR辅助案例CCC 成员：制造模拟导致癌症的人类突变的小鼠；鉴定癌症易感性 基因定位；产生用于体内肿瘤成像的小鼠；以及研究与肿瘤相关的基因的基本生物学 癌症。这个SR是克利夫兰地区唯一的转基因核，它为整个 区域。因此，它得到了CWRU的大力支持。所有Case CCC成员都可以共同访问此 托管SR。

TRANSGENIC AND TARGETING SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Transgenic and Targeting Shared Resource (Transgenic SR) is an essential asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of scientific program involvement and reflected in the large number of investigators who use this SR. Last year alone, 45 investigators, 40% of whom were Case CCC members, accounting for 39% of total usage, from 5 out of 7 of the Center’s programs used the SR. The Transgenic SR makes transgenic, chimeric, knockout, and knock-in mice and provides services in rederivation, cryopreservation, reanimation, in vitro fertilization and surgery. Central to the success of investigators with new mouse genetic models is the role this facility plays in consultation, education and training, as well as support after service. The Specific Aims of the Transgenic SR are to: 1. Provide Case CCC members with consultation, education and training. The Director of the Transgenic SR consults with Cancer Center members and their research staff to ensure they utilize the best technology to meet their experimental goals. The rapid evolution of CRISPR/Cas9 technologies makes consultation particularly important. 2. Provide Case CCC members with new mouse genetic models. The Transgenic SR generates the genetic variants of mice in a timely and cost-effective manner. 3. Provide Case CCC members with follow-up support through direct interaction and through the wealth of information available on the facility website. At last review, the Transgenic SR was rated Outstanding Merit. Throughout the current funding cycle (2012- 2016), the Transgenic SR provided services to 133 registered users, 41 (31%) of whom are Case CCC members, representing 5 of the Center’s 7 Programs. The Transgenic SR has had great success in gene targeting using CRISPR/Cas9. Since 2014, the SR has successfully completed over 30 new gene-targeted mutations in mice using this approach, the vast majority of which have been disease-causing missense mutations. The Transgenic SR is in the vanguard of transgenic cores in applying CRISPR/Cas9 technology. In the last funding period, the Transgenic SR assisted Case CCC members in: generating mice that model human mutations leading to cancer; identifying cancer susceptibility loci; generating mice for in vivo imaging of tumors; and investigating the basic biology of genes implicated in cancer. This SR is the only transgenic core in the Cleveland area, and it serves investigators throughout the region. As a consequence, it is strongly supported by CWRU. All Case CCC members have access to this jointly managed SR.